Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention

被引：96

作者：

Vivekananthan, DP

Bhatt, DL

Chew, DP

Zidar, FJ

Chan, AW

Moliterno, DJ

Ellis, SG

Topol, EJ

机构：

[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Desk F25, Cleveland, OH 44195 USA

[2] Flinders Med Ctr, Adelaide, SA, Australia

[3] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 03期

关键词：

D O I：

10.1016/j.amjcard.2004.04.035

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study sought to determine the effect of clopidogrel pretreatment on the increase in C-reactive protein (CRP) after percutaneous coronary intervention. Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model. (C) 2004 by Excerpto Medica, Inc.

引用

收藏

页码：358 / 360

页数：3

相关论文

共 19 条

[1] Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban) [J].

Assali, AR ;

Salloum, J ;

Sdringola, S ;

Moustapha, A ;

Ghani, M ;

Hale, S ;

Schroth, G ;

Fujise, K ;

Anderson, HV ;

Smalling, RW ;

Rosales, OR .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (08) :884-+

[2]

Berglund Ulf, 2002, J Invasive Cardiol, V14, P243

[3] Scientific and therapeutic advances in antiplatelet therapy [J].

Bhatt, DL ;

Topol, EJ .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (01) :15-28

[4] Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - Results from the do tirofiban and ReoPro give similar efficacy outcome trial (TARGET) [J].

Chan, AW ;

Moliterno, DJ ;

Berger, PB ;

Stone, GW ;

DiBattiste, PM ;

Yakubov, SL ;

Sapp, SK ;

Wolski, K ;

Bhatt, DL ;

Topol, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (07) :1188-1195

[5] Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein [J].

Chew, DP ;

Bhatt, DL ;

Robbins, MA ;

Mukherjee, D ;

Roffi, M ;

Schneider, JP ;

Topol, EJ ;

Ellis, SG .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (06) :672-674

[6] INTRAMYOCARDIAL PLATELET-AGGREGATION IN PATIENTS WITH UNSTABLE ANGINA SUFFERING SUDDEN ISCHEMIC CARDIAC DEATH [J].

DAVIES, MJ ;

THOMAS, AC ;

KNAPMAN, PA ;

HANGARTNER, JR .

CIRCULATION, 1986, 73 (03) :418-427

[7]

FRINK RJ, 1988, BRIT HEART J, V59, P196

[8] Soluble CD40 ligand in acute coronary syndromes [J].

Heeschen, C ;

Dimmeler, S ;

Hamm, CW ;

van den Brand, MJ ;

Boersma, E ;

Zeiher, AM ;

Simoons, ML ;

CAPTURE Study Investigators .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (12) :1104-1111

[9] CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J].

Henn, V ;

Slupsky, JR ;

Gräfe, M ;

Anagnostopoulos, I ;

Förster, R ;

Müller-Berghaus, G ;

Kroczek, RA .

NATURE, 1998, 391 (6667) :591-594

[10] Platelet CD40 ligand (CD40L) -: subcellular localization, regulation of expression, and inhibition by clopidogrel [J].

Hermann, A ;

Rauch, BH ;

Braun, M ;

Schrör, K ;

Weber, AA .

PLATELETS, 2001, 12 (02) :74-82